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Inhibitory receptors on natural killer cells and on a
minority of T lymphocytes are major histocompat-
ibility complex class Ia or Ib speci®c. We have pre-
viously reported several tumor-speci®c cytotoxic T
cell clones in®ltrating a CD4+ Vb13+ cutaneous T
cell lymphoma. These clones mediated a speci®c
major histocompatibility complex class I-restricted
cytotoxic activity toward the uncultured tumor cells
and autologous long-term tumor T cell lines. In this
study, we cultured with interleukin-2 the peripheral
blood lymphocytes of the same patient a few weeks
before invasion of the blood by tumor cells. We
report the rapid and selective expansion of a CD8+
Vb13+ lymphoid population. This population was
clonal, as it expressed a unique T cell receptor-Vb
junctional region. Vb13+ tumor cells and Vb13+ reac-
tive T cells were shown to have different junctional
sequences. The CD8+ reactive clone was functional,
as it had a speci®c autologous tumor-speci®c, human
leukocyte antigen-A2 restricted, cytotoxic activity.
This clone coexpressed high levels of CD158a,
CD158b, p70, and CD94/NKG2A inhibitory recep-
tors. Interestingly, we found that anti-CD158a and
anti-CD158b monoclonal antibodies could inhibit
anti-CD3 redirected cytotoxicity mediated by the
reactive clonal population. Further, an anti-human
leukocyte antigen-B/C monoclonal antibody enhanced
the speci®c cytotoxic activity of the clone against auto-
logous tumor cells. These results are the ®rst evidence
that inhibitory receptor expression can lead to the
inhibition of cutaneous T cell lymphoma-speci®c T cell
responses. Key words: cutaneous T cell lymphoma/inhibitory
receptors/T cell clone. J Invest Dermatol 115:994±999, 2000
I
nhibitory receptors are major histocompatibility complex
(MHC) class Ia/Ib-speci®c receptors that have recently been
reported on natural killer cells (Lanier, 1998). The well-
known susceptibility of some cell lines to the so-called
natural killer lysis is attributable to the absence of MHC class
I expression by these cell lines (Ljunggren and Karre, 1990). There
are several natural killer receptors, speci®c for different MHC class I
alleles (Moretta and Moretta, 1997). In humans, inhibitory
receptors are subdivided into two structural types of molecules
that display a different speci®city. One consists of immuno-
globulin superfamily inhibitory receptors, which encompass several
members, termed killer cell immunoglobulin-like receptors (KIR),
characterized by several extracellular immunoglobulin-like
domains, that speci®cally recognize human leukocyte antigen
(HLA) -C (p58.1/CD158a and p58.2/CD158b) (Moretta et al,
1990, 1993, 1995; Wagtmann et al, 1995), HLA-B (p70/NKB-1)
(Litwin et al, 1993; Lanier et al, 1995; Vitale et al, 1996), and
HLA-A (p140) (Pende et al, 1996) alleles. The other type comprises
type II membrane molecules that belong to the C-type lectin
inhibitory receptors. These receptors are composed of CD94
covalently associated with NKG2A molecules, which display a
speci®city toward self MHC peptides presented by HLA-E (Braud
et al, 1998). Recently, inhibitory receptors have also been shown to
be expressed on a subset of activated T cells (mainly CD8+) in
which they can inhibit T cell receptor mediated functions (Mingari
et al, 1997). Both families of receptors transduce negative signals to
cytotoxic lymphocytes after their ligation with MHC class I
molecules. The negative signal is associated with two tyrosine-x-x-
leucine (YXXL) sequences in the cytoplasmic tail, termed
immunoreceptor tyrosine-based inhibitory motif (Bensussan,
1998).
We have previously reported several tumor-speci®c cytotoxic T
cell clones in®ltrating a cutaneous T cell lymphoma (CTCL) (Bagot
et al, 1998). These clones, although they had a CD4+ phenotype,
mediated a speci®c MHC class I-restricted cytotoxic activity
toward the uncultured tumor cells and autologous long-term tumor
T cell lines. In this study, we cultured in the presence of interleukin
(IL) ±2 the peripheral blood lymphocytes of the same patient at an
early phase, before the invasion of the blood by tumor cells, and in
the absence of tumor cells. We report the rapid selective expansion
of a clonal T cell receptor (TCR) -Vb13+ CD8+ tumor-speci®c
cytotoxic cell population. We show that this reactive Vb13+ CD8+
T cell clonal population, which was already detectable in the blood,
was different from the Vb13+ tumor cells and expressed several
functional inhibitory receptors, including CD158a, and CD158b,
that led to the inhibition of its speci®c anti-tumor cytotoxic
activity.
MATERIALS AND METHODS
Patient A 81 y old man presented with disseminated pruriginous
in®ltrated patches and plaques that had been present for 8 y. There was
no palpable lymph node. The skin biopsy revealed an epidermotropic
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in®ltrate composed of small atypical lymphocytes with a cerebriform
nucleus. A diagnosis of mycosis fungoides, or epidermotropic CTCL (stage
Ib) was made. The phenotype of skin tumor cells was CD3+ CD2±
CD5+ CD7± CD4+ CD8± TCR-a/b+ TCR-g/d± MHC class I+ MHC class
II±. Serology for human T cell lymphotropic virus-1 was negative. The
patient was treated with topical mechlorethamine, which induced a
complete remission. Two years later, identical lesions recurred, and the
patient was treated with PUVA therapy, which again induced a complete
remission. Three years later, the patient presented with disseminated skin
tumors. The skin biopsy showed a nonepidermotropic in®ltrate composed
of large pleomorphic cells. The phenotype of tumor cells was unchanged.
Despite a treatment with polychemotherapy and radiotherapy, the patient
died after 6 mo of disseminated infection. Skin and blood samples were
taken at different periods after informed consent. Ethical committee
approval for the study was obtained.
Tumor cell lines Fresh CTCL tumor cells were obtained from
mechanically dispersed tumor fragments. The tumor T cell line Cou-L
was cultured as already reported (Bagot et al, 1998). Fresh CTCL cells and
Cou-L failed to express MHC class II molecules and were HLA-A*0101,
A*0201, and HLA-B*3503 and B*5101. The clonal origin of the growing
cell line was systematically tested by analyzing the clonal reactivity with an
anti-TCR-Vb13 monoclonal antibody and by TCR-Vb transcripts analysis
(Bagot et al, 1998).
Culture of the T cell line DEN-1 To expand the T cell population
DEN-1, patient peripheral blood mononuclear cells were isolated using
Ficoll-Isopaque density gradient centrifugation (Pharmacia, Piscataway,
NJ), and cultured at 106 cells per ml in RPMI 1640 supplemented with
2 mmol per l L-glutamine, penicillin (100 U per ml), streptomycin (100 mg
per ml), 10% heat-inactivated human serum, and 25 U per ml recombinant
IL-2. Cultures were fed every 3 d for 4 wk with recombinant IL-2-
containing medium. It should be noted that no irradiated tumor cells were
used as stimulator cells for the expansion of DEN-1.
Monoclonal antibodies (MoAb) and phenotypic analysis MoAb
such as phycoerythrin (PE) -conjugated or ¯uorescein isothiocyanate
(FITC) -conjugated anti-CD4 and anti-CD8 were purchased from
Beckman Coulter (Marseille, France). The anti-TCR-Vb13 MoAb was
obtained from BIOadvance (Emerainville, France). Dr P. Le Bouteiller
(INSERM, Toulouse, France) kindly provided: (i) MoAb B1.23.2, which
reacts with monomorphic determinants shared by HLA-B, HLA-C, and
only a few HLA-A alleles; (ii) MoAb L243, reactive with monomorphic
determinants shared by HLA-DR, HLA-DP, and HLA-DQ; and (iii) the
anti-HLA-A2 MoAb BB7.2. The anti-inhibitory receptors MoAb,
including EB6 (anti-CD158a), GL183 (anti-CD158b), NKB1 (anti-p70),
NKH3 (anti-CD94), and Z270 (anti-NKG2A), were obtained through the
exchanges of the sixth and seventh international workshops on the human
leukocyte differentiation antigens. The anti-CD1a MoAb O10 was
produced in our laboratory. These MoAb were used as ascite ¯uids
hybridoma supernatants. Phenotypic analysis was performed, using a single
argon ¯ow cytometer analyzer (Epics XL, Coulter, Miami, FL). Indirect
immuno¯uorescence assays were performed, using a FITC-conjugated goat
anti-mouse immunoglobulin from Caltag Laboratories (San Francisco, CA)
or a PE-labeled goat anti-mouse immunoglobulin from Beckman Coulter.
Two-color analyses were performed as already described (Bagot et al,
1998).
Cytotoxicity assays Cytotoxicity assays were performed according to a
standard 51Cr-release method. Assays at various effector to target cell (E/T)
ratios with 5 3 103 51Cr-labeled target cells per well were carried out in
triplicate, using 96-well V-bottomed microtiter plates. For blocking
experiments, the target cells were incubated for 20 min with the
appropriate MoAb, and subsequently washed before being used in the
cytotoxic assay. The ®nal culture volume was 200 ml per well. After 4 h of
culture, plates were spun and 100 ml of supernatant was removed from each
well and counted in a gamma-counter for the determination of 51Cr
release. The percentage of lysis was determined as previously described
(MaõÈza et al, 1993). For the antibody-redirected cytolytic assay, the murine
mastocytoma cell line P815 was used as source of target cells, as previously
described (Echchakir et al 2000). Brie¯y, DEN-1 effector cells were
incubated with various concentrations of an anti-CD3 MoAb alone or in
combination with an anti-CD158a, an anti-CD158b, or an irrelevant
anti-CD1a MoAb (O10) of similar isotype (IgG1), before the addition of
51Cr-labeled P815 target cells at an E/T ratio of 10/1.
Directed sequencing of polymerase chain reaction (PCR)
products PCR products were obtained as described elsewhere (Bagot
et al, 1998), and were puri®ed using Qiagen columns (Qiaquick PCR
puri®cation kit, Hilden, Germany), and resuspended in 20 ml of sterile
water. The puri®ed products were directly sequenced in both directions
with a PRISM ready reactions DyeDeoxy Terminator cycle sequencing kit
and a 373-A DNA sequencer (Applied Biosystems, Foster City, CA).
RESULTS AND DISCUSSION
Rapid expansion of a CD8+ Vb13+ reactive T cell clonal
population Flow cytometric analysis performed with peripheral
blood lymphocytes of the patient revealed a minor population of
CD8+ lymphoid cells, and a major population of CD4+ cells.
Looking for the presence of Vb13+ CD4+ tumor cells in the blood,
we found within the CD8+ population a small but signi®cant subset
of CD8+ Vb13+ cells, whereas no CD4+ Vb13+ tumor cells were
detectable at that time (Fig 1). Culture with IL-2 alone selectively
and rapidly expanded this CD8+ Vb13+ lymphoid population, that
became predominant after 28 d and was named DEN-1 (Fig 1). All
TCR-Vb13+ lymphocytes were found within the CD8+ subset,
and few Vb13± CD4+ and Vb13± CD8+ lymphocytes were still
present in the culture after 28 d. The TCR-b VDJ sequence of
DEN-1 was determined and compared with the TCR-Vb13
junctional region of the tumor T cell line Cou-L. As shown in
Table I, DEN-1 was found to be a clonal population, because a
unique junctional region sequence was obtained with Vb13 and Cb
primers. Both Cou-L and DEN-1 expressed Vb13.2-Jb2.5 TCR
transcripts, but their TCR-Vb junctional sequences were different.
This T cell population was not related to the tumor cells previously
reported (Bagot et al, 1998), as it failed to contain a trisomy 7,
found on fresh tumor cells as well as on long-term tumor T cell
lines. Furthermore, we could distinguish tumor cells from the
reactive T cell line, as the former failed to express MHC class II
molecules, whereas the latter expressed high amounts of HLA-DR,
-DP, and -DQ molecules (data not shown).
The cytotoxic activity of the CD8+ Vb13+ T cell clonal
population is restricted by HLA-A2 and enhanced by an
anti-HLA-B/C MoAb The cytotoxic activity of the 4 wk
cultured clone DEN-1 was measured against different target cells:
the autologous tumor T cell line Cou-L (Fig 2A), the MHC class
I-negative natural killer-susceptible cell line K562, and the
allogeneic tumor T cell line PNO (Fig 2B). The results showed
that DEN-1 had both a tumor-speci®c cytotoxic activity on Cou-L
and a natural killer-like cytotoxic activity on K562. The natural
killer-like reactivity of DEN-1 against the MHC class I-negative
target cell line K562 can be attributable to the clonal CD8+ Vb13+
autologous tumor-speci®c population, as we already reported
MHC class I-restricted cytotoxic T cell clones exhibiting a natural
killer-like reactivity (David et al, 1987). In contrast, DEN-1 had no
cytotoxic activity against the allogeneic tumor T cell line PNO.
The autologous tumor-speci®c cytotoxic activity was restricted by
HLA-A2, as it was inhibited by preincubation of the target cells
with the HLA-A2-speci®c MoAb BB7.2 (Fig 2A), whereas the
preincubation with the control MoAb L243 had no effect (data not
shown). The autologous tumor-speci®c reactivity of DEN-1 was
attributable to the CD8+ Vb13+ major cell subset, as removal of
Vb13+ cells with magnetic beads completely abolished the tumor-
speci®c cytotoxic activity (data not shown). Interestingly, we found
that the anti-tumoral cytotoxic activity of DEN-1 was strongly
enhanced by the preincubation of the target cells with the MoAb
B1.23.2, which binds HLA-B/C molecules (Fig 2A). It must be
noted that the preincubation of K562 or PNO with B1.23.2 MoAb
did not modify the results obtained in Fig 2(B) (data not shown). In
order to further demonstrate the MHC class I-restricted anti-tumor
cytotoxic activity of DEN-1, we cultured this clone in the absence
of IL-2 for 3 d. These culture conditions allowed us to dissociate
the natural killer-like cytotoxicity, which almost disappeared, from
the speci®c cytotoxicity occurring via CD3/TCR engagement,
which was maintained (Fig 2C). Thus, the cytotoxic activity
mediated against autologous tumor cells by DEN-1 could not be
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attributed to its natural killer-like activity observed with the
presence of high amounts of IL-2 in the culture medium.
The CD8+ Vb13+ T cell clonal population expresses several
inhibitory receptors In order to determine whether the
increase of the anti-tumoral cytotoxic activity of DEN-1,
induced by the addition of an anti-HLA-B/C MoAb, was due to
the blocking of the interaction of KIR with the HLA-B or -C
molecules expressed by tumor cells, we studied the expression of
several KIR and CD94/NKG2A by the tumor-speci®c cytotoxic T
cell clone DEN-1. As shown in Fig 3, DEN-1 expressed high
levels of several inhibitory receptors, including CD158a, CD158b,
p70, and CD94/NKG2A. It should be noted that an identical
staining pro®le was obtained with anti-CD94 and anti-NKG2A
MoAb (data not shown). In contrast, the Vb13+ tumor T cell line
Cou-L did not express any of the inhibitory receptors tested. Both
DEN-1 and the tumor cell line were CD56± (data not shown). The
recognition of HLA class I molecules on tumor cells by these
inhibitory receptors clearly inhibited the speci®c cytotoxic activity
of DEN-1 on autologous tumor cells, as addition of an anti-HLA-
B/C MoAb strongly enhanced this speci®c cytotoxic activity. This
increase of the speci®c cytotoxic activity of DEN-1 could not be
Figure 1. Rapid expansion of a CD8+ Vb13+
T cell population from the blood of a patient
with a CD4+ Vb13+ cutaneous T cell lympho-
ma. Double immunostaining ¯ow-cytometric
analysis was performed, using a PE-conjugated or
an FITC-conjugated anti-CD4 MoAb, a PE-
conjugated anti-CD8, and an anti-Vb13 MoAb
plus a FITC-conjugated goat anti-mouse immuno-
globulin. Labeling was performed by incubating the
cells with the anti-Vb13 MoAb for 20 min, then the
FITC-conjugated goat anti-mouse immunoglobulin
was added for 30 min. The cells were washed and
incubated with a saturating amount of mouse
immunoglobulins before adding the conjugated
MoAb.
Table I. VDJ sequences of Cou-L and DEN-1
Cell line Vb Framework CDR3 Framework Jb
Cou-L 13.2 TGT GCC AGC AG C CCC AGC GGG CGG AAA CAA GAG ACC 2.5
DEN-1 13.2 TGT GCC AGC AG T TAC TCT TTA GGT AGC GGG AGT ACC TAC AAT GAG CAG 2.5
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attributable to antibody-dependent cell cytotoxicity, as an isotype-
matched MoAb reacting with the tumor cells failed to increase the
lysis (data not shown). Furthermore, as the CD158a and CD158b
receptors can be expressed as activatory or inhibitory isoform
receptors (Bensussan, 1998; Lanier, 1998), we tested whether the
stimulation of these receptors in DEN-1 cells might provide the
inhibition of their anti-CD3 MoAb-redirected cytolytic activity. As
shown in Table II, the results clearly indicate that triggering of
CD158a or CD158b in DEN-1 cells induced a signi®cant
inhibition of the anti-CD3 MoAb-redirected cytolysis, whereas
an isotype-matched control with an irrelevant antibody had no
effect. Finally, it remained to determine the exact contribution of
the inhibitory signal provided by the interaction of CD94/NKG2A
molecules with HLA-E expressed by the tumor target cell.
Inhibitory receptors are MHC class I-speci®c receptors that have
recently been reported on natural killer cells. Some T lymphocytes,
including a minority of a/b T cells, and a fraction of g/d T cells,
also express the MHC class I-binding inhibitory receptors found on
Figure 2. The cytotoxic activity of the
CD8+ Vb13+ T cell clonal population DEN-1
is restricted by HLA-A2 and enhanced by an
anti-HLA-B/C MoAb. The cytotoxic activity of
DEN-1 was measured against different target cells:
the autologous tumor T cell line Cou-L (A), the
MHC-class I-negative natural killer-susceptible
cell line K562, and the allogeneic tumor T cell
line PNO (B). DEN-1 was cultured in the
absence of recombinant IL-2 for 3 d. The cyto-
toxic activity was then tested both on the auto-
logous tumor cell line Cou-L and K562 (C).
Results are expressed as percentages of speci®c
lysis.
Figure 3. The CD8+ Vb13+ T cell clone expresses several inhibitory receptors. Flow-cytometric analysis was performed, using diluted ascites of
several MoAb directed against inhibitory receptors (anti-CD158a, CD158b, p70, and CD94/NKG2A) or an anti-Vb13 MoAb, plus a FITC-conjugated
goat anti-mouse immunoglobulin.
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natural killer cells (Lanier, 1998; Mingari et al, 1998). Inhibitory
receptor-expressing T lymphocytes have been found in peripheral
lymphoid organs, but not in the thymus. They usually have a
memory CD8 phenotype, and an oligoclonal Vb repertoire. It has
been shown that the recognition of the corresponding HLA class I
molecule by a KIR can inhibit the cytotoxic activity and the
cytokine production by a T cell clone (Mingari et al, 1995;
D'Andrea et al, 1996; Le DreÂan et al, 1998). The HLA-speci®c
inhibitory receptors on such T cells may allow preferential lysis of
cells that have downregulated the expression of the appropriate
HLA class I molecules. In one patient with melanoma, the
cytotoxic activity of a TCR-a/b+, HLA-A24-restricted, in vitro
raised T cell clone speci®c for the PRAME gene product, was
inhibited by the interaction of a p58.2 inhibitory receptor expressed
by the tumor reactive clone with the HLA-Cw7 class I molecule
present on tumor cells (Ikeda et al, 1997). The subsequent loss of
HLA-Cw7 unblocked the inhibitory signal, that limited the killing
of tumor cells. Such cytotoxic clones, active against tumor cells
showing partial HLA loss, may constitute an intermediate line of
anti-tumor defense between the cytotoxic lymphocytes, recogniz-
ing highly speci®c tumor antigens, and the broadly reactive natural
killer cells, recognizing HLA loss variants (Ikeda et al, 1997).
Moreover, it has been shown that disrupting interactions of KIR
with their ligands on tumor cells may enhance melanoma-speci®c
anti-tumor responses mediated by both innate and adaptive
immune effector cells (Bakker et al, 1998). Expression of inhibitory
receptors by tumor-speci®c cytotoxic lymphocytes may therefore
lead to an altered anti-tumor immune response. In addition, a
recent study demonstrated the expression of KIR by human
melanoma-speci®c cytolytic T lymphocytes in vivo (Speiser et al,
1999). Apoptosis of cytotoxic clones can also be induced by the
triggering of KIR molecules (Nakajima et al, 1998).
In this study, we show the rapid and selective expansion of a
circulating CD8+ CTCL-reactive clonal population. This clonal
expansion was obtained ex vivo without any stimulation with the
tumor cells. In addition, we found that inhibitory receptor
expression could be responsible for the inhibition of its speci®c
MHC-restricted cytotoxic activity, and may therefore represent an
escape mechanism able to antagonize CTCL-speci®c cytotoxic
responses. As expression of KIR (in contrast to CD94/NKG2A) is
not acquired during the in vitro culture with IL-2, these ®ndings
might have clinical relevance, because this minor speci®cally
cytotoxic population was detected a few weeks before the invasion
of the blood by tumoral CD4+ T cells. In addition, we tested the
expression of CD94/NKG2A on fresh patient peripheral blood
lymphocytes before culture. Results show that the CD8+ Vb13+
population present at that time in the blood was stained by the anti-
NKG2A MoAb Z270 (data not shown). The expression of
inhibitory receptors by this reactive T cell clone may have
contributed to the lack of ef®cacy of the immune response of the
patient against his tumor, and to the dissemination of the disease,
although the evidence that there is inhibition of cytotoxicity in vivo
is still weak. These data also suggest that strategies modulating
inhibitory receptor expression or function could increase the
ef®cacy of immunotherapy in cutaneous lymphomas.
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